Chronic myeloid leukaemia (CML) statistics

Cases

New cases of chronic myeloid leukaemia, 2014-2016 average, UK

Deaths

Deaths from chronic myeloid leukaemia, 2015-2017, UK.

  • There are around 220 chronic myeloid leukaemia deaths in the UK every year, that's more than 4 every week (2015-2017).
  • Chronic myeloid leukaemia accounted for less than 1% of all cancer deaths (2017).
  • In females in the UK, chronic myeloid leukaemia accounted for around 100 deaths in 2017.
  • In males in the UK, chronic myeloid leukaemia accounted for around 140 deaths in 2017.
  • Incidence rates for chronic myeloid leukaemia in the UK are highest in people aged 85 to 89 (2014-2016).
  • Since the early 1990s, chronic myeloid leukaemia incidence rates have decreased by around a third (32%) in the UK. Rates in females have decreased by more than a quarter (29%) and rates in males have decreased by almost two-fifths (39%).
  • Over the last decade, chronic myeloid leukaemia incidence rates have remained stable in the UK. Rates in females have remained stable, and rates in males have remained stable.
  • Leukaemia (CML) incidence in England is not associated with deprivation.
  • An estimated 6,000 people who had previously been diagnosed with chronic myeloid leukaemia (CML) were alive in the UK at the end of 2010.

See more in-depth CML incidence statistics

  • There are around 220 chronic myeloid leukaemia deaths in the UK every year, that's more than 4 every week (2015-2017).
  • Chronic myeloid leukaemia accounted for less than 1% of all cancer deaths (2017).
  • In females in the UK, chronic myeloid leukaemia accounted for around 100 deaths in 2017.
  • In males in the UK, chronic myeloid leukaemia accounted for around 140 deaths in 2017.
  • Mortality rates for chronic myeloid leukaemia in the UK are highest in people aged 90+ (2014-2016).
  • Since the early 1970s, chronic myeloid leukaemia mortality rates have decreased by more than seven-tenths (72%) in the UK. Rates in females have decreased by around three-quarters (76%), and rates in males have decreased by around seven-tenths (71%).
  • Over the last decade, chronic myeloid leukaemia mortality rates have decreased by around a fifth (19%) in the UK. Rates in females have decreased by around a quarter (24%), and rates in rates in males have remained stable.
  • Leukaemia (CML) deaths in England are more common in males living in the most deprived areas. There is no association for females.

See more in-depth CML mortality statistics

  • Five-year relative survival for CML (Chronic myeloid leukaemia) in men is similar to the European average in England, Scotland and Wales.
  • Five-year relative survival for CML (Chronic myeloid leukaemia) in women is similar to the European average in England, Wales and Northern Ireland but above the European average in Scotland.

See more in-depth CML survival statistics

Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.